{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:04Z","timestamp":1759017844728,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12185-025-04009-w","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:55:35Z","timestamp":1748008535000},"page":"546-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia"],"prefix":"10.1007","volume":"122","author":[{"given":"Hiroaki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Matsunawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"22","key":"4009_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091\u2013101.","journal-title":"N Engl J Med"},{"issue":"12","key":"4009_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"5","key":"4009_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021;56(5):1126\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4009_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12185-023-03596-w","volume":"118","author":"Y Najima","year":"2023","unstructured":"Najima Y. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. Int J Hematol. 2023;118(2):169\u201382.","journal-title":"Int J Hematol"},{"issue":"2","key":"4009_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","volume":"107","author":"T Schroeder","year":"2018","unstructured":"Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107(2):138\u201350.","journal-title":"Int J Hematol"},{"issue":"1","key":"4009_CR6","first-page":"1","volume":"13","author":"K Matsuoka","year":"2024","unstructured":"Matsuoka K. Post-transplant maintenance therapy: emerging concepts and future perspectives. Jpn J Transplant Cell Ther. 2024;13(1):1\u201313.","journal-title":"Jpn J Transplant Cell Ther"},{"issue":"12","key":"4009_CR7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668\u201379.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4009_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21(4):653\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"4009_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41409-020-01039-2","volume":"56","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, Bergmann A, Pechtel S, et al. Wilm\u2019s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transplant. 2021;56(2):442\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4009_CR10","first-page":"1279","volume":"46","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Emi N, Mitani K, et al. Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Rinsho Ketsueki. 2005;46(12):1279\u201387.","journal-title":"Rinsho Ketsueki"},{"issue":"8","key":"4009_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/sj.leu.2403809","volume":"19","author":"M Weisser","year":"2005","unstructured":"Weisser M, Kernb W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19(8):1416\u201323.","journal-title":"Leukemia"},{"issue":"31","key":"4009_CR12","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195\u2013201.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4009_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4149\/neo_2013_011","volume":"60","author":"J Polak","year":"2013","unstructured":"Polak J, Hajkova H, Haskovec C, et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia \u2013 a useful tool for early detection of minimal residual disease. Neoplasma. 2013;60(1):74\u201382.","journal-title":"Neoplasma"},{"issue":"4","key":"4009_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.12181","volume":"160","author":"S Pozzi","year":"2013","unstructured":"Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol. 2013;160(4):503\u20139.","journal-title":"Br J Haematol"},{"issue":"1","key":"4009_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/bmt.2014.209","volume":"50","author":"A Israyelyan","year":"2015","unstructured":"Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(1):26\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4009_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","volume":"103","author":"K Kitamura","year":"2016","unstructured":"Kitamura K, Nishiyama T, Ishiyama K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103(1):53\u201362.","journal-title":"Int J Hematol"},{"issue":"8","key":"4009_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-016-2706-y","volume":"95","author":"XD Mo","year":"2016","unstructured":"Mo XD, Qin YZ, Zhang XH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95(8):1233\u201340.","journal-title":"Ann Hematol"},{"issue":"2","key":"4009_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cam4.593","volume":"5","author":"M Malagola","year":"2016","unstructured":"Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med. 2016;5(2):265\u201374.","journal-title":"Cancer Med"},{"issue":"4","key":"4009_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/bmt.2016.318","volume":"52","author":"R Dul\u00e9ry","year":"2017","unstructured":"Dul\u00e9ry R, Nibourel O, Gauthier J, et al. Impact of Wilms\u2019 tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52(4):539\u201343.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4009_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.bbmt.2019.05.033","volume":"25","author":"BS Cho","year":"2019","unstructured":"Cho BS, Min GJ, Park SS, et al. WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: optimal time points, thresholds, and candidates. Biol Blood Marrow Transplant. 2019;25(10):1925\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"4009_CR21","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Lambert J, Thomas X, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5(23):5258\u201368.","journal-title":"Blood Adv"},{"issue":"12","key":"4009_CR22","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.3390\/jcm11123306","volume":"11","author":"D Lazzarotto","year":"2022","unstructured":"Lazzarotto D, Candoni A. The role of Wilms\u2019 tumor gene (WT1) expression as a marker of minimal residual disease in acute myeloid leukemia. J Clin Med. 2022;11(12):3306.","journal-title":"J Clin Med"},{"issue":"3","key":"4009_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12185-024-03795-z","volume":"120","author":"S Arai","year":"2024","unstructured":"Arai S, Tachibana T, Izumi A, et al. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Int J Hematol. 2024;120(3):337\u201346.","journal-title":"Int J Hematol"},{"issue":"26","key":"4009_CR24","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4009_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4009_CR26","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600\u201311.","journal-title":"Lancet Haematol"},{"issue":"18","key":"4009_CR27","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"7","key":"4009_CR28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4009_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","volume":"7","author":"T Terao","year":"2023","unstructured":"Terao T, Matsuoka K, Ueda H, et al. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3 mut AML. Blood Adv. 2023;7(5):681\u20136.","journal-title":"Blood Adv"},{"issue":"15","key":"4009_CR30","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4009_CR31","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M de Lima","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420\u201331.","journal-title":"Cancer"},{"issue":"21","key":"4009_CR32","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia GM, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580\u20138.","journal-title":"Blood Adv"},{"issue":"36","key":"4009_CR33","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, et al. Effect of G-CSF combined with decitabine prophylaxis on relapse of patients with high risk MRD-negative AML after HSCT: an open label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):4249\u201359.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4009_CR34","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021;112(9):3636\u201344.","journal-title":"Cancer Sci"},{"key":"4009_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.HS9.0000845132.53694.7f","volume":"6","author":"C Craddock","year":"2022","unstructured":"Craddock C, Platzbecker U, Heuser M, et al. VIALE-T: a randomized, open-label, phase 3 study of venetoclax in combination with azacitidine after allogeneic stem cell transplantation in patients with acute myeloid leukemia. HemaSphere. 2022;6:460\u20131.","journal-title":"HemaSphere"},{"issue":"15","key":"4009_CR36","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood.2019004685","volume":"136","author":"N Saini","year":"2020","unstructured":"Saini N, Marin D, Ledesma C, et al. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020;136(15):1786\u20139.","journal-title":"Blood"},{"issue":"3","key":"4009_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4009_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","volume":"115","author":"IS Luis","year":"2010","unstructured":"Luis IS, Silvia G, Carlos S, et al. Immunomodulatory effect of 5-azacytidine(5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107\u201321.","journal-title":"Blood"},{"key":"4009_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00277-020-04051-0","volume":"99","author":"M Yanada","year":"2020","unstructured":"Yanada M, Takami A, Yamasaki S, et al. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. Ann Hematol. 2020;99:1351\u201360.","journal-title":"Ann Hematol"},{"issue":"10","key":"4009_CR40","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/ajh.27417","volume":"99","author":"S Garciaz","year":"2024","unstructured":"Garciaz S, Dumas PY, et al. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol. 2024;99(10):1870\u20136.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04009-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:52:12Z","timestamp":1758955932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04009-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04009-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TakayoshiT reports honoraria from Pfizer, Otsuka, AbbVie, Chugai, Asahikasei-pharma, Astellas, Amgen, Novartis, and Nippon-Shinyaku, outside the submitted work. TakahiroS reports honoraria from Kyowa Kirin, Novartis, Alexion, and Chugai, outside the submitted work. HN reports honoraria from Novartis and Daiichi-Sankyo, scholarships from Daiichi-Sankyo, Celgene, Chugai, Nihon-Shinyaku, Astellas, Asahikasei-pharma, Takeda, Pfizer, and Eisai, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}